"We are only beginning to understand the complex role of innate immune activation in the brain, and this is especially true in both normal and pathological aging," Thanos said. "If we can pinpoint which cells and signals sustain that activation, we will be in a much better position to intervene effectively in disease."
Beyond Alzheimer’s, the implications of this research extend to a wide array of neurodegenerative conditions. Because STING responds to the fundamental biological process of DNA damage—a common thread in many diseases of the nervous system—it may play a similar role in Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and various forms of dementia. This opens the possibility of a "universal" approach to treating neurodegeneration by stabilizing the brain’s immune response.
The Road to Translation
While the findings are a significant breakthrough, Lukens and his team emphasize that there is a long road ahead before these results can be translated into clinical treatments for human patients. One of the primary challenges lies in the fact that STING is a vital part of the body’s overall immune health.
For instance, STING plays a crucial role in the body’s ability to detect and fight cancer cells. An immune system with no STING activity at all might be unable to mount a defense against tumors or viral infections. Therefore, any future drug would need to be carefully calibrated to "dampen" STING activity in the brain without completely shutting down its essential functions elsewhere in the body.
"Our hope is that this work moves us close to finding safer and more effective ways to protect the aging brain, as there is an urgent need for treatments that can slow or prevent neuronal damage in Alzheimer’s," Lukens said. "Shedding light on how STING contributes to that damage may help us target similar molecules and ultimately develop effective disease-modifying treatments."
The ongoing work is being accelerated by the resources of UVA’s Paul and Diane Manning Institute of Biotechnology. The Harrison Family Translational Research Center, where the study was conducted, is a key component of this institute, which is currently expanding its facilities at Fontaine Research Park. The goal of the institute is to fast-track "bench-to-bedside" research, ensuring that laboratory discoveries like the STING pathway can be developed into viable therapies as quickly and safely as possible.
Findings Published
The comprehensive study, which involved a multidisciplinary team of scientists including Olivia C. Campbell, Maureen N. Cowan, Katherine R. Bruch, Katelyn A. Moore, Hannah E. Ennerfelt, Nick R. Natale, Aman Mangalmurti, and Nagaraj Kerur, was made possible through significant support from the National Institutes of Health (NIH). Specific grants from the National Institute of Aging provided the backbone for the research, alongside contributions from the Alzheimer’s Association, the Cure Alzheimer’s Fund, and the Harrison and Owens Family Foundations.
As the research moves into its next phase, the scientific community will be watching closely to see if the STING pathway holds the key to finally unlocking a cure for the world’s most devastating memory-robbing diseases. For now, the UVA discovery provides a new sense of direction and hope in a field that has long been defined by its complexity and challenges.
